|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:activities
|
inhibits IL-4 and IL-13 signaling
|
|
gptkbp:appointed_by
|
gptkb:Person
adults
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2017
gptkb:FDA
|
|
gptkbp:clinical_trial
|
Phase 3
LIBERTYADTRIALS
LIBERTYASTHMATRIALS
LIBERTYNPTRIALS
|
|
gptkbp:contraindication
|
active infection
hypersensitivity to dupilumab
|
|
gptkbp:dosage_form
|
gptkb:software_framework
|
|
gptkbp:formulation
|
auto-injector
pre-filled syringe
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dupilumab
|
|
gptkbp:indication
|
chronic rhinosinusitis with nasal polyps
moderate to severe atopic dermatitis
moderate to severe asthma
|
|
gptkbp:ingredients
|
gptkb:dupilumab
C_30 H_31 N_7 O_7 S
|
|
gptkbp:interacts_with
|
none significant
|
|
gptkbp:invention
|
2027
|
|
gptkbp:is_monitored_by
|
allergic reactions
respiratory symptoms
eye symptoms
|
|
gptkbp:is_used_for
|
gptkb:asthma
atopic dermatitis
chronic rhinosinusitis with nasal polyps
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:manufacturer
|
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:USA
gptkb:Native_American_tribe
|
|
gptkbp:population
|
adults with asthma
adults with chronic rhinosinusitis
children with atopic dermatitis
|
|
gptkbp:price
|
high
|
|
gptkbp:research_areas
|
dermatology
immunology
pulmonology
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
headache
injection site reactions
conjunctivitis
pharyngitis
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:IL-13_receptor
gptkb:IL-4_receptor
|
|
gptkbp:traded_on
|
gptkb:Dupixent
|
|
gptkbp:weight
|
145 k Da
|
|
gptkbp:bfsParent
|
gptkb:Dupixent
|
|
gptkbp:bfsLayer
|
4
|